

<p style="text-align: center;"><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>Form PTO-1449 (Modified) (Use several sheets if necessary)</p> <p>DEC 01 2003</p>				<b>COMPLETE IF KNOWN</b>	
<p>Sheet <b>1</b> of <b>3</b></p> <p><i>RECEIVED U.S. PATENT AND TRADEMARK OFFICE OCT 1 2003</i></p>		<p>Application Number <b>10/734,858</b></p> <p>Confirmation Number <b>1526</b></p> <p>Filing Date <b>December 11, 2003</b></p> <p>First Named Inventor <b>Kozlowski et al.</b></p> <p>Group Art Unit <b>1711</b></p> <p>Examiner Name <b>Acuah, S.</b></p> <p>Attorney Docket No. <b>41714.8001</b></p>			

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		NUMBER	Kind Code			
<i>SA</i>	1	4670417		Iwasaki et al.	06/1987	
	2	5252714		Harris et al.	10/1993	
	3	5281698		Nitecki.	01/1994	
	4	5468478		Saifer et al.	11/1995	
	5	5650234		Dolence et al.	07/1997	
	6	5672662		Harris et al.	09/1997	
	7	5824784		Kinstler et al.	10/1998	
	8	5900461		Harris.	05/1999	
	9	5932462		Harris et al.	08/1999	
<i>SA</i>	10	6348558		Harris et al.	02/2002	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				
<i>SA</i>	11	PCT	WO 99/45964			09/1999		
<i>SA</i>	12	PCT	WO 01/26692			04/2001		

### OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.						
<i>SA</i>	13	Abuchowski et al., "Cancer Therapy with Chemically Modified Enzymes. I. Antitumor Properties of Polyethylene Glycol-Asparaginase Conjugates," <i>Cancer Biochem. Biophys.</i> , 7:175-186 (1984).						
<i>SA</i>	14	Andresz et al., <i>Makromol. Chem.</i> , 179:301-312 (1978).						
<i>SA</i>	15	Beauchamp et al., "A New Procedure for Synthesis of Polyethylene Glycol-Protein Adducts; Effects on Function, Receptor Recognition, and Clearance of Superoxide Dismutase, Lactoferrin, and $\alpha$ 2-Macroglobulin," <i>Analytical Biochemistry</i> , 131:25-33 (1983).						

EXAMINER

*SA* A. Acuah

DATE CONSIDERED

02/20/06

\*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
Form PTO-1449 (Modified)  
(Use several sheets if necessary)

COMPLETE IF KNOWN	
Application Number	10/734,858
Confirmation Number	1526
Filing Date	December 11, 2003
First Named Inventor	Kozlowski et al.
Group Art Unit	1711
Examiner Name	Acquah, S.
Attorney Docket No.	41714.8001

Sheet

2

of

3

16	Brinkley, M. A brief survey of methods for preparing protein conjugates with dyes, haptens, and cross-linking reagents. <i>Bioconjug. Chem.</i> 3:2-13 (1992).
17	Buckman et al., "Functionalization of Poly(ethylene glycol) and Monomethoxy-Poly(ethylene glycol)," <i>Makromol. Chem.</i> , 182:1379-1384 (1981).
18	Duncan, R.J., Weston, P.D., Wrigglesworth, R. A new reagent which may be used to introduce sulphydryl groups into proteins, and its use in the preparation of conjugates for immunoassay. <i>Anal. Biochem.</i> 132(1):68-73 (1983).
19	Elling et al., "Immunoaffinity Partitioning: Synthesis and Use of Polyethylene Glycol-Oxirane for Coupling to Bovine Serum Albumin and Monoclonal Antibodies," <i>Biotechnology and Applied Biochemistry</i> , 13:354-362 (1991).
20	Goodson et al., "Site-Directed PEGylation of Recombinant Interleukin-2 at its Glycosylation Site," <i>Bio/Technology</i> , 8(4):343-346, (1990).
21	Greenwald et al., "Highly Water Soluble Taxol Derivatives: 7-Polyethylene Glycol Carbamates and Carbonates," <i>J. Org. Chem.</i> , 60:331-336 (1995).
22	Harris et al., "Synthesis and Characterization of Poly(ethylene glycol) Derivatives," <i>J. Polym. Sci. Chem. Ed.</i> , 22:341-352 (1984).
23	Joppich et al., "Synthesis of Glycyl-L-tryptophylglycine Substituted by Poly(ethylene oxide) at both the Carboxy and the Amino End Groups," <i>Makromol. Chem.</i> , 180:1381-1384 (1979).
24	Kogan, "The Synthesis of Substituted Methoxy-Poly(ethylene glycol) Derivatives Suitable for Selective Protein Modification," <i>Synthetic Communications</i> , 22(16):2417-2424 (1992).
25	Mattson, G., Conklin, E., Desai, S., Nielander, G., Savage, M.D. and Morgensen, S. A practical approach to crosslinking. <i>Mol. Biol. Rep.</i> 17(3):167-183 (1993).
26	Means, G.E. and Feeney, R.E. Chemical modifications of proteins: history and applications. <i>Bioconjug. Chem.</i> 1:2-12 (1990).
27	Okamoto et al., "Kinetic Study on Reactions Between Polymer Chain-Ends--II. Reactions Between Chlorosulphonyl-Ended and Primary Amino-Ended Polyoxyethylenes Followed by Fluorometry", <i>Eur. Polym. J.</i> , 19(4):341-346 (1983).
28	Pitha et al., "Detergents Linked to Polysaccharides: Preparation and Effects on Membranes and Cells," <i>Eur. J. Biochem.</i> , 94:11-18 (1979).
29	Sartore et al., "Enzyme Modification by MPEG with an Amino Acid or Peptide as Spacer Arms," <i>Applied Biochemistry and Biotechnology</i> , 27:45-54 (1991).

EXAMINER

*Sam A. Acquah*

DATE CONSIDERED

*02/20/06*

\*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				COMPLETE IF KNOWN	
Form PTO-1449 (Modified) (Use several sheets if necessary)				Application Number	10/734,858
				Confirmation Number	1526
				Filing Date	December 11, 2003
				First Named Inventor	Kozlowski et al.
				Group Art Unit	1711
				Examiner Name	Acquah, S.
Sheet	3	of	3	Attorney Docket No.	41714.8001

30	Sawhney et al., "Bioerodible Hydrogels Based on Photopolymerized Poly(ethylene glycol)-co-poly( $\alpha$ -hydroxy acid) Diacrylate Macromers," <i>Macromolecules</i> , <b>26</b> :581-587 (1993).
31	Tondelli et al., "Poly(Ethylene Glycol) Imidazolyl Formates as Oligomeric Drug-Binding Matrices," <i>Journal of Controlled Release</i> , <b>1</b> :251-257 (1985).
32	Veronese et al., "Activation of Monomethoxy-Polyethylene Glycols by Phenylchloroformates and Modification of Ribonuclease and Superoxide Dismutase," <i>Applied Biochemistry and Biotechnology</i> , <b>11</b> :141-152 (1985).
33	Woghiren et al., "Protected Thiol-Polyethylene Glycol: A New Activated Polymer for Reversible Protein Modification," <i>Bioconjugate Chem.</i> , <b>4</b> :314-318 (1993).
34	Wong, S.S. and Wong, L.J. Chemical crosslinking and the stabilization of proteins and enzymes. <i>Enzyme Microb. Technol.</i> <b>14</b> :866-874 (1992).
35	Zalipsky et al., "Attachment of Drugs to Polyethylene Glycols," <i>Eur. Polym. J.</i> , <b>19</b> (12):1177-1183 (1983).
36	Zalipsky, "Chemistry of polyethylene glycol conjugates with biologically active molecules", <i>Advanced Drug Delivery Reviews</i> , <b>16</b> :157-182 (1995).
37	Product description from Shearwater Polymers, Inc., pp. 2-49. (1995).
38	Catalog of "Polyethylene Glycol Derivatives" from Shearwater Polymers, Inc.; pp. 1-53 (1997-1998).
39	Catalog of "Polyethylene Glycol and Derivatives" from Shearwater Polymers, Inc., pp. 1-50 (2000).
40	Catalog of "Polyethylene Glycol and Derivatives for Biomedical Applications" from Shearwater Polymers, Inc., pp. 1-17 (2001)
41	Nektar Molecule Engineering Catalog of "Polyethylene Glycol Derivatives for Advanced PEGylation", pp. 1-21 (2003).
42	Catalog of "PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals" from NOF Corporation; pp. 1-46 (2003, 1 <sup>st</sup> ed).
43	Catalog of "PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals" from NOF Corporation; pp. 1-50 (2003, 2 <sup>nd</sup> ed).

EXAMINER <i>Sam A. Acquah</i>	DATE CONSIDERED <i>02/20/06</i>
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	